Navigation Links
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Date:5/21/2013

OXFORD, England, May 22, 2013 /PRNewswire/ --

First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform

Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on lung function and the safety of a range of doses in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The first two groups of eight patients, from up to 40 patients being enrolled, have been dosed at the Medicines Evaluation Unit in Manchester, UK, where the study is being conducted under the supervision of Professor Dave Singh . Further details of the study are below.

PSX1002 is a novel formulation of glycopyrronium bromide (GB), a long-acting muscarinic antagonist (LAMA), that is being developed as a potential 'best-in-class' orally inhaled monotherapy for COPD.  PSX1002 was designed using Prosonix' proprietary particle engineering technology platform, which has enabled the Company to create, and initiate clinical studies with a simple suspension formulation of GB for delivery via a pressurised metered dose inhaler (pMDI) that does not require or contain any other extraneous carriers or functional excipients.

Dr Geoff Down , Prosonix Chief Medical Officer, added: "Glycopyrronium bromide appears to be particularly useful in reversing airway constriction in COPD patients, increasing airflow, relieving symptoms and improving quality of life. We look forward to the results in 2014."

David Hipkiss , CEO of Prosonix commented: "This trial with PSX1002 is a very exciting step for Prosonix as it marks the first ever
'/>"/>

SOURCE Prosonix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Eckert ... Accelerator Mass Spectrometry (AMS) services to the pharmaceutical and ... has joined the company in the position of Director ... years of broad and valuable experience in drug metabolism ...
(Date:1/22/2015)... January 21, 2015 Cambridge Semantics, the leading ... today announced that 2014 was a record-breaking year across the ... of the Anzo Smart Data Platform and our Smart Data ... insights from diverse data which led to record growth for ...
(Date:1/22/2015)... January 22, 2015 zFlo Motion , ... to announce an exciting product from a new partner. ... solutions over the past 15 years, with offerings in the ... their 3D IMU system (inertial measurement unit), iSen, is opening ...
(Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... BOSTON, Mass.With the potential to save tens of thousands ... developed by MassBiologics at the University of Massachusetts and ... forward with positive results from a Phase 1 study. ... antibody (RAB-1) resulted in protective antibody levels in the ...
... Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) (the "Company") ... Shareholders (the "Annual Meeting") held on Thursday, September 16, ... John H. Bauer and Phillip M. Nudelman, M.D. to ... Company,s 2013 Annual Meeting. Shareholders approved the proposals to ...
... BRUNSWICK, N.J., Sept. 15 On Sept. 23 ... N.J. will host Contracting & Outsourcing 2010, the ... Contract Pharma Magazine. This year,s Conference will feature ... Contract Manufacturing at Pfizer, covering Global Pharma Outsourcing ...
Cached Biology Technology:New treatment for rabies advances after successful phase 1 trial in India 2New treatment for rabies advances after successful phase 1 trial in India 3Cell Therapeutics, Inc. Reports Outcome of Annual Meeting of Shareholders 2Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010 2
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
(Date:1/22/2015)... , Europe,s most prestigious innovation ... to present a video retrospective of the most exciting and innovative ... Toumazou and Sophie Wilson   A different ...   Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile commerce ... consultant, Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the NXT-ID booth ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... 17, 2009) Tufts University researchers have identified a gene-diet ... replicated their findings in three independent studies. Men and ... index (BMI) scores and a higher incidence of obesity, ... saturated fat. These associations were seen in the apolipoprotein ...
... , REDWOOD CITY, Calif., Nov. 17 DigitalPersona, ... solutions, today announced that its customer, Picis, has ... and privacy protection for its Picis ED PulseCheck® ... U.are.U® Fingerprint Readers and One Touch® for Windows ...
... WASHINGTON DC, NOVEMBER 16, 2009 Experts in soil ... will present a Congressional educational briefing, "The Essence of Earth ... in 2168 Rayburn House Office Building (Gold Room). ... concept of "terroir" -- how the balance of vineyard management ...
Cached Biology News:Nutrigenomics researchers replicate gene interaction with saturated fat 2Nutrigenomics researchers replicate gene interaction with saturated fat 3Picis ED PulseCheck Increases Security and Privacy Protection in Nearly 150 Hospitals Through the Use of DigitalPersona Biometrics 2Picis ED PulseCheck Increases Security and Privacy Protection in Nearly 150 Hospitals Through the Use of DigitalPersona Biometrics 3Soil experts to discuss terroir, the link between Earth, wine on Nov. 19 in DC 2
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... 100-240 V, uses xMAP technology for simultaneous ... and peptides in one microplate well. The ... 100 color-coded bead sets, each of which ... (enzyme substrates, receptors, antigens, or antibodies) specific ...
...
Biology Products: